Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Human platelets Clear all
Completed Phase 1Phase 2 Interventional

Recombinant Human Thrombopoietin in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy

NCT00187109
View directory record Official record
Conditions
Germ Cell Tumors, Hepatic Cancer, Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma
Interventions
Recombinant Human Thrombopoietin
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
View directory record Official record
Conditions
Macular Degeneration
Interventions
GW786034, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Not applicable Interventional

Platelet Derived Growth Factor Stimulates Bone Fill and Rate of Attachment Level Gain

NCT01530126
View directory record Official record
Conditions
Periodontitis
Interventions
B-TCP + 0.3 mg/ml rhPDGF-BB in buffer, B-TCP + 1.0 mg/ml rhPDGF-BB in buffer, B-TCP +buffer
Biological
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional

Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding

NCT01561950
View directory record Official record
Conditions
Haemostasis, Healthy
Interventions
eptacog alfa (activated), clopidogrel, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional

CAM Procedure With BMAC for Shoulder OA

NCT04826224
View directory record Official record
Conditions
Shoulder Osteoarthritis
Interventions
Concentrated bone marrow aspirate administration after Comprehensive Arthroscopic Management (CAM) surgical procedure.
Biological
Lead sponsor
Shane A. Shapiro
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional Results available

Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)

NCT05457491
View directory record Official record
Conditions
Skin Aging
Interventions
Human platelet extract (cosmetic product), Vanicream Gentle Facial Cleanser, EltaMD UV Daily Broad-Spectrum SPF 40, EltaMD PM Therapy Facial Moisturizer, Vanicream Lite Lotion
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

rHGH and Intestinal Permeability in Intestinal Failure

NCT01380366
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Somatropin, Seven Day Food Diary, Blood Tests (standard of care), Fasting, Sugar Permeability Test, Urine Collection
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Ketorolac on Platelet Function Post-Cesarean Delivery

NCT03805607
View directory record Official record
Conditions
Analgesia, Obstetrical, Coagulation Defect; Postpartum, Nonsteroidals (NSAIDs)Toxicity, Postpartum Hemorrhage, Postoperative Pain, Ketorolac Adverse Reaction, Blood Loss, Postoperative
Interventions
Ketorolac Tromethamine 30 MG/ML, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)

NCT02223117
View directory record Official record
Conditions
Healthy
Interventions
Thrombosomes, Placebo
Biological
Lead sponsor
Cellphire Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Sep 13, 2026, 5:49 AM EDT
Completed No phase listed Observational

Observational Registry of the Treatment of Glanzmann's Thrombasthenia

NCT01476423
View directory record Official record
Conditions
Congenital Bleeding Disorder, Glanzmann's Disease
Interventions
activated recombinant human factor VII
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Recombinant Human Platelet-derived Growth Factor in Combination With Collagen Matrix

NCT04462237
View directory record Official record
Conditions
Gingival Recession, Platelet Derived Growth Factor
Interventions
Root coverage procedures
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 13, 2026, 5:49 AM EDT
Active, not recruiting Early Phase 1 Interventional

Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide

NCT03910452
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Busulfan, Alemtuzumab, Cyclophosphamide, Sirolimus, Total Body Irradiation, Allogeneic peripheral blood stem cell
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

NCT02137889
View directory record Official record
Conditions
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Interventions
VAY736
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 2 Interventional Results available

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

NCT02098109
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma, Non-Hodgkin
Interventions
XM02 Filgrastim, Filgrastim, Apheresis, Plerixafor, Stem Cell Transplant
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 17, 2017 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Delivering Transcutaneous Auricular Neurostimulation to Regulate Platelet Activity in Healthy Human Subjects

NCT05977946
View directory record Official record
Conditions
Hemostasis, Blood Biomarkers
Interventions
Volta System
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

NCT03324373
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy
Drug · Procedure
Lead sponsor
Yousef Zakharia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Sep 13, 2026, 5:49 AM EDT
Withdrawn Not applicable Interventional

Assessment of Outcome of Meniscus Repair With or Without Platelet Rich Plasma

NCT00961597
View directory record Official record
Conditions
Cartilage Disease
Interventions
Meniscus repair for red/white tears without PRP, Meniscus repair with PRP
Procedure
Lead sponsor
Sue Barber-Westin
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 2 Interventional

Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

NCT06634030
View directory record Official record
Conditions
Wound Healing, Surgical Wound
Interventions
RhPDGF-BB, Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
22 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor

NCT04954664
View directory record Official record
Conditions
Dental Implant, Bone Loss
Interventions
Allograft particles hydrated with rhPDGF, Allograft particles hydrated in a conventional way with saline.
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 28, 2025 · Synced Sep 13, 2026, 5:49 AM EDT
Completed No phase listed Observational

Effects of Antibodies to White Blood Cells on Platelet Transfusion Patients

NCT00460122
View directory record Official record
Conditions
Healthy, Transfusion Reactions
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

pAF for the Treatment of Osteoarthritis

NCT04886960
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Amniotic Fluid Injection, Standard of Care
Biological · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease

NCT03414645
View directory record Official record
Conditions
Dry Eye, Graft-versus-host-disease, Ocular Discomfort
Interventions
CAM-101 10%, Vehicle Control, CAM-101 30%
Biological
Lead sponsor
Cambium Bio Limited
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Palo Alto, California • Boston, Massachusetts • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 13, 2026, 5:49 AM EDT
Active, not recruiting Phase 1 Interventional

Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A

NCT03818763
View directory record Official record
Conditions
Hemophilia A
Interventions
Auto CD34+PBSC, transduced with a lentiviral vector encoding the B domain deleted from of human coagulation factor VIII
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 13, 2026, 5:49 AM EDT